Literature DB >> 16648096

Bad patients meet good drugs.

Juan Carlos Lacal.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16648096     DOI: 10.1007/BF02664931

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


× No keyword cloud information.
  13 in total

Review 1.  The BCR gene and philadelphia chromosome-positive leukemogenesis.

Authors:  E Laurent; M Talpaz; H Kantarjian; R Kurzrock
Journal:  Cancer Res       Date:  2001-03-15       Impact factor: 12.701

Review 2.  The protein kinase complement of the human genome.

Authors:  G Manning; D B Whyte; R Martinez; T Hunter; S Sudarsanam
Journal:  Science       Date:  2002-12-06       Impact factor: 47.728

Review 3.  Oncogenic kinase signalling.

Authors:  P Blume-Jensen; T Hunter
Journal:  Nature       Date:  2001-05-17       Impact factor: 49.962

4.  Failing survival advantage in crucial trial, future of Iressa is in jeopardy.

Authors:  Renee Twombly
Journal:  J Natl Cancer Inst       Date:  2005-02-16       Impact factor: 13.506

5.  Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

Authors:  T G Lugo; A M Pendergast; A J Muller; O N Witte
Journal:  Science       Date:  1990-03-02       Impact factor: 47.728

Review 6.  Gastrointestinal stromal tumor: 5 years later.

Authors:  Sanne M van der Zwan; Ronald P DeMatteo
Journal:  Cancer       Date:  2005-11-01       Impact factor: 6.860

Review 7.  Philadelphia chromosome-positive acute lymphocytic leukemia.

Authors:  J P Radich
Journal:  Hematol Oncol Clin North Am       Date:  2001-02       Impact factor: 3.722

Review 8.  Epidermal growth factor receptor (EGFR) inhibitors in cancer therapy.

Authors:  Fortunato Ciardiello; Ferdinando De Vita
Journal:  Prog Drug Res       Date:  2005

9.  Overriding imatinib resistance with a novel ABL kinase inhibitor.

Authors:  Neil P Shah; Chris Tran; Francis Y Lee; Ping Chen; Derek Norris; Charles L Sawyers
Journal:  Science       Date:  2004-07-16       Impact factor: 47.728

Review 10.  Imatinib as a paradigm of targeted therapies.

Authors:  Brian J Druker
Journal:  Adv Cancer Res       Date:  2004       Impact factor: 6.242

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.